Sunshine Biopharma (SBFM) Competitors

$1.04 -0.01 (-1.24%)

As of 02:44 PM Eastern

SBFM vs. LPCN, PASG, NCEL, CVKD, and GNTA

Should you be buying Sunshine Biopharma stock or one of its competitors? The main competitors of Sunshine Biopharma include Lipocine (LPCN), Passage Bio (PASG), NLS Pharmaceutics (NCEL), Cadrenal Therapeutics (CVKD), and Genenta Science (GNTA). These companies are all part of the "pharmaceutical products" industry.

How does Sunshine Biopharma compare to Lipocine?

Sunshine Biopharma (NASDAQ:SBFM) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment.

Sunshine Biopharma presently has a consensus target price of $7.00, indicating a potential upside of 575.02%. Lipocine has a consensus target price of $15.00, indicating a potential upside of 539.66%. Given Sunshine Biopharma's higher possible upside, equities research analysts plainly believe Sunshine Biopharma is more favorable than Lipocine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sunshine Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

In the previous week, Lipocine had 4 more articles in the media than Sunshine Biopharma. MarketBeat recorded 5 mentions for Lipocine and 1 mentions for Sunshine Biopharma. Sunshine Biopharma's average media sentiment score of 0.54 beat Lipocine's score of -0.51 indicating that Sunshine Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sunshine Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lipocine	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Sunshine Biopharma has a net margin of -17.86% compared to Lipocine's net margin of -571.18%. Sunshine Biopharma's return on equity of -27.14% beat Lipocine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sunshine Biopharma	-17.86%	-27.14%	-21.14%
Lipocine	-571.18%	-66.70%	-59.39%

42.0% of Sunshine Biopharma shares are owned by institutional investors. Comparatively, 9.1% of Lipocine shares are owned by institutional investors. 0.0% of Sunshine Biopharma shares are owned by insiders. Comparatively, 6.4% of Lipocine shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Sunshine Biopharma has higher revenue and earnings than Lipocine. Lipocine is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sunshine Biopharma	$36.31M	0.14	-$5.97M	-$1.48	N/A
Lipocine	$1.98M	9.76	-$9.63M	-$1.88	N/A

Sunshine Biopharma has a beta of 1.37, indicating that its share price is 37% more volatile than the S&P 500. Comparatively, Lipocine has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500.

Summary

Sunshine Biopharma beats Lipocine on 12 of the 17 factors compared between the two stocks.

How does Sunshine Biopharma compare to Passage Bio?

Sunshine Biopharma (NASDAQ:SBFM) and Passage Bio (NASDAQ:PASG) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

Sunshine Biopharma presently has a consensus target price of $7.00, suggesting a potential upside of 575.02%. Passage Bio has a consensus target price of $13.25, suggesting a potential upside of 201.82%. Given Sunshine Biopharma's higher probable upside, equities analysts clearly believe Sunshine Biopharma is more favorable than Passage Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sunshine Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Passage Bio	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Passage Bio has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -17.86%. Sunshine Biopharma's return on equity of -27.14% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sunshine Biopharma	-17.86%	-27.14%	-21.14%
Passage Bio	N/A	-135.04%	-60.37%

42.0% of Sunshine Biopharma shares are held by institutional investors. Comparatively, 53.5% of Passage Bio shares are held by institutional investors. 0.0% of Sunshine Biopharma shares are held by company insiders. Comparatively, 4.9% of Passage Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Sunshine Biopharma has higher revenue and earnings than Passage Bio. Sunshine Biopharma is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sunshine Biopharma	$36.31M	0.14	-$5.97M	-$1.48	N/A
Passage Bio	N/A	N/A	-$45.52M	-$14.48	N/A

In the previous week, Sunshine Biopharma and Sunshine Biopharma both had 1 articles in the media. Sunshine Biopharma's average media sentiment score of 0.54 beat Passage Bio's score of 0.00 indicating that Sunshine Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sunshine Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Passage Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sunshine Biopharma has a beta of 1.37, indicating that its share price is 37% more volatile than the S&P 500. Comparatively, Passage Bio has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500.

Summary

Sunshine Biopharma and Passage Bio tied by winning 7 of the 14 factors compared between the two stocks.

How does Sunshine Biopharma compare to NLS Pharmaceutics?

NLS Pharmaceutics (NASDAQ:NCEL) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

In the previous week, Sunshine Biopharma had 1 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 1 mentions for Sunshine Biopharma and 0 mentions for NLS Pharmaceutics. Sunshine Biopharma's average media sentiment score of 0.54 beat NLS Pharmaceutics' score of 0.00 indicating that Sunshine Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
NLS Pharmaceutics	Neutral
Sunshine Biopharma	Positive

NLS Pharmaceutics has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500. Comparatively, Sunshine Biopharma has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500.

NLS Pharmaceutics has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -17.86%. NLS Pharmaceutics' return on equity of 0.00% beat Sunshine Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
Sunshine Biopharma	-17.86%	-27.14%	-21.14%

Sunshine Biopharma has higher revenue and earnings than NLS Pharmaceutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
Sunshine Biopharma	$36.31M	0.14	-$5.97M	-$1.48	N/A

42.0% of Sunshine Biopharma shares are owned by institutional investors. 16.4% of NLS Pharmaceutics shares are owned by company insiders. Comparatively, 0.0% of Sunshine Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Sunshine Biopharma has a consensus price target of $7.00, suggesting a potential upside of 575.02%. Given Sunshine Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Sunshine Biopharma is more favorable than NLS Pharmaceutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sunshine Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Sunshine Biopharma beats NLS Pharmaceutics on 9 of the 13 factors compared between the two stocks.

How does Sunshine Biopharma compare to Cadrenal Therapeutics?

Cadrenal Therapeutics (NASDAQ:CVKD) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

Cadrenal Therapeutics has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500. Comparatively, Sunshine Biopharma has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500.

In the previous week, Cadrenal Therapeutics had 3 more articles in the media than Sunshine Biopharma. MarketBeat recorded 4 mentions for Cadrenal Therapeutics and 1 mentions for Sunshine Biopharma. Cadrenal Therapeutics' average media sentiment score of 0.76 beat Sunshine Biopharma's score of 0.54 indicating that Cadrenal Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cadrenal Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sunshine Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

7.9% of Cadrenal Therapeutics shares are owned by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are owned by institutional investors. 26.1% of Cadrenal Therapeutics shares are owned by insiders. Comparatively, 0.0% of Sunshine Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Cadrenal Therapeutics currently has a consensus price target of $13.00, indicating a potential upside of 130.91%. Sunshine Biopharma has a consensus price target of $7.00, indicating a potential upside of 575.02%. Given Sunshine Biopharma's higher probable upside, analysts plainly believe Sunshine Biopharma is more favorable than Cadrenal Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sunshine Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Sunshine Biopharma has higher revenue and earnings than Cadrenal Therapeutics. Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$5.63	N/A
Sunshine Biopharma	$36.31M	0.14	-$5.97M	-$1.48	N/A

Cadrenal Therapeutics has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -17.86%. Sunshine Biopharma's return on equity of -27.14% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cadrenal Therapeutics	N/A	-411.03%	-275.61%
Sunshine Biopharma	-17.86%	-27.14%	-21.14%

Summary

Sunshine Biopharma beats Cadrenal Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Sunshine Biopharma compare to Genenta Science?

Genenta Science (NASDAQ:GNTA) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

Genenta Science has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500. Comparatively, Sunshine Biopharma has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500.

Sunshine Biopharma has higher revenue and earnings than Genenta Science.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A
Sunshine Biopharma	$36.31M	0.14	-$5.97M	-$1.48	N/A

Genenta Science has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -17.86%. Genenta Science's return on equity of 0.00% beat Sunshine Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genenta Science	N/A	N/A	N/A
Sunshine Biopharma	-17.86%	-27.14%	-21.14%

In the previous week, Sunshine Biopharma had 1 more articles in the media than Genenta Science. MarketBeat recorded 1 mentions for Sunshine Biopharma and 0 mentions for Genenta Science. Sunshine Biopharma's average media sentiment score of 0.54 beat Genenta Science's score of 0.00 indicating that Sunshine Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Genenta Science	Neutral
Sunshine Biopharma	Positive

15.1% of Genenta Science shares are owned by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are owned by institutional investors. 29.0% of Genenta Science shares are owned by insiders. Comparatively, 0.0% of Sunshine Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Sunshine Biopharma has a consensus price target of $7.00, indicating a potential upside of 575.02%. Given Sunshine Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Sunshine Biopharma is more favorable than Genenta Science.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sunshine Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Sunshine Biopharma beats Genenta Science on 9 of the 13 factors compared between the two stocks.

Get Sunshine Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SBFM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SBFM vs. The Competition

Export

Metric	Sunshine Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.18M	$3.38B	$6.20B	$12.30B
Dividend Yield	N/A	2.24%	2.78%	5.22%
P/E Ratio	-0.71	15.24	20.71	25.86
Price / Sales	0.14	281.71	549.99	74.51
Price / Cash	N/A	56.93	27.81	36.27
Price / Book	0.22	7.00	9.82	6.79
Net Income	-$5.97M	$24.11M	$3.55B	$333.31M
7 Day Performance	N/A	N/A	N/A	0.56%
1 Month Performance	3.87%	5.45%	6.77%	9.42%
1 Year Performance	-17.37%	79.61%	42.65%	43.23%

Sunshine Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SBFM Sunshine Biopharma	2.7644 of 5 stars	$1.04 -1.2%	$7.00 +575.0%	-16.3%	$5.18M	$36.31M	N/A	3
LPCN Lipocine	3.0632 of 5 stars	$2.31 -2.5%	$15.00 +549.4%	-27.7%	$19.02M	$1.98M	N/A	10	Earnings Report Gap Down
PASG Passage Bio	3.2548 of 5 stars	$5.78 +1.2%	$13.25 +129.2%	-36.1%	$18.54M	N/A	N/A	130	News Coverage Upcoming Earnings
NCEL NLS Pharmaceutics	0.6682 of 5 stars	$3.35 -13.4%	N/A	-79.5%	$17.64M	N/A	N/A	6	Gap Down
CVKD Cadrenal Therapeutics	2.9577 of 5 stars	$5.33 -6.5%	$13.00 +143.9%	-57.3%	$17.55M	N/A	N/A	4	Earnings Report Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SBFM) was last updated on 5/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sunshine Biopharma (SBFM) Competitors

SBFM vs. LPCN, PASG, NCEL, CVKD, and GNTA

How does Sunshine Biopharma compare to Lipocine?

Summary

How does Sunshine Biopharma compare to Passage Bio?

Summary

How does Sunshine Biopharma compare to NLS Pharmaceutics?

Summary

How does Sunshine Biopharma compare to Cadrenal Therapeutics?

Summary

How does Sunshine Biopharma compare to Genenta Science?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBFM vs. The Competition

Sunshine Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sunshine Biopharma (SBFM) Competitors

SBFM vs. LPCN, PASG, NCEL, CVKD, and GNTA

How does Sunshine Biopharma compare to Lipocine?

Do analysts rate SBFM or LPCN?

Does the media prefer SBFM or LPCN?

Is SBFM or LPCN more profitable?

Do institutionals and insiders believe in SBFM or LPCN?

Which has preferable earnings and valuation, SBFM or LPCN?

Which has more volatility and risk, SBFM or LPCN?

Summary

How does Sunshine Biopharma compare to Passage Bio?

Do analysts prefer SBFM or PASG?

Is SBFM or PASG more profitable?

Do insiders & institutionals hold more shares of SBFM or PASG?

Which has preferable earnings and valuation, SBFM or PASG?

Does the media prefer SBFM or PASG?

Which has more risk & volatility, SBFM or PASG?

Summary

How does Sunshine Biopharma compare to NLS Pharmaceutics?

Does the media refer more to NCEL or SBFM?

Which has more risk and volatility, NCEL or SBFM?

Is NCEL or SBFM more profitable?

Which has higher valuation and earnings, NCEL or SBFM?

Do institutionals and insiders hold more shares of NCEL or SBFM?

Do analysts prefer NCEL or SBFM?

Summary

How does Sunshine Biopharma compare to Cadrenal Therapeutics?

Which has more risk & volatility, CVKD or SBFM?

Does the media favor CVKD or SBFM?

Do insiders and institutionals believe in CVKD or SBFM?

Do analysts recommend CVKD or SBFM?

Which has higher earnings & valuation, CVKD or SBFM?

Is CVKD or SBFM more profitable?

Summary

How does Sunshine Biopharma compare to Genenta Science?

Which has more risk & volatility, GNTA or SBFM?

Which has higher earnings & valuation, GNTA or SBFM?

Is GNTA or SBFM more profitable?

Does the media favor GNTA or SBFM?

Do insiders and institutionals believe in GNTA or SBFM?

Do analysts recommend GNTA or SBFM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBFM vs. The Competition

Sunshine Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools